Company intelligence / Profile preview

Monument Biosciences

Indianapolis, Indiana, United Statesmonument.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Monument Biosciences is a preclinical-stage biopharmaceutical company focused on developing next-generation disease-modifying drugs for Alzheimer’s Disease and related dementias. Their programs are anchored in human patient genetics and recent discoveries around tau biology and microglial neuroinflammation. The company leverages translational biomarkers to guide clinical strategy and patient selection but has not yet reported clinical results as of May 2025.

Therapeutic areas: Neurology
Modalities: Small molecules (inferred from "diverse therapeutic modalities" and typical approaches in neurodegeneration)Potential combination therapies
Industry: Biotech

Beyond the preview

Go deeper on Monument Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monument Biosciences.

Explore the full profile